Results from ALICE - Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial

被引：0
|
作者：
Kyte, Jon Amund
Rossevold, Andreas H.
Andresen, Nikolai K.
Bjerre, Christina Annette
Gilje, Bjornar
Jakobsen, Erik Hugger
Raj, Sunil Xavier
Falk, Ragnhild Sorum
Borgen, Elin
Jahr, Thea
Garred, Oystein
Lomo, Jon
Mathiesen, Randi Margit
Naume, Bjorn
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD11-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD11-11
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.
    Moreno-Aspitia, A.
    Rowland, K. M.
    Liu, H.
    Hillman, D. W.
    Stella, P. J.
    Perez, E. A.
    CANCER RESEARCH, 2011, 71
  • [32] Immunogenicity of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple negative breast cancer
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Ge, Xuan
    Lee, Jin Sun
    Frankel, Paul H.
    Cui, Yujie
    Ruel, Christopher
    Schmolze, Daniel
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Lee, Peter
    Waisman, James
    Yuan, Yuan
    CANCER RESEARCH, 2023, 83 (05)
  • [33] A Phase 2 trial of RAD 001 and Carboplatin in patients with triple negative metastatic breast cancer
    Singh, J. C.
    Volm, M.
    Novik, Y.
    Speyer, J.
    Adams, S.
    Omene, C. O.
    Meyers, M.
    Smith, J. A.
    Schneider, R.
    Formenti, S.
    Goldberg, J. D.
    Li, X.
    Davis, S.
    Beardslee, B.
    Tiersten, A.
    CANCER RESEARCH, 2012, 72
  • [34] Phase Ib trial of olinvacimab and pembrolizumab in patients with metastatic triple-negative breast cancer
    Chan, Arlene
    Moylan, Eugene
    Jackson, Sally
    Devoto, Jeannette
    Jones, Nicola
    Radmil, Silvie
    Wilkinson, Kate
    Roohullah, Aflah
    Adam, Tamiem
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin-San
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
    Singh, Jasmeet Chadha
    Novik, Yelena
    Stein, Stacey
    Volm, Matthew
    Meyers, Marlene
    Smith, Julia
    Omene, Coral
    Speyer, James
    Schneider, Robert
    Jhaveri, Komal
    Formenti, Silvia
    Kyriakou, Victoria
    Joseph, Benson
    Goldberg, Judith D.
    Li, Xiaochun
    Adams, Sylvia
    Tiersten, Amy
    BREAST CANCER RESEARCH, 2014, 16 (02):
  • [36] Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
    Yuan, Yuan
    Yost, Susan E.
    Cui, Yujie
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Schmolze, Daniel
    Waisman, James
    Patel, Niki
    Vora, Lalit
    Tumyan, Lusine
    Bozoghlanian, Mari
    Stewart, Daphne
    Frankel, Paul H.
    ONCOLOGIST, 2023, 28 (07): : E498 - E507
  • [37] Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer
    Liu, Yun
    Qiu, Nasha
    Shen, Limei
    Liu, Qi
    Zhang, Jing
    Cheng, Yung-Yi
    Lee, Kuo-Hsiung
    Huang, Leaf
    JOURNAL OF CONTROLLED RELEASE, 2020, 323 : 431 - 441
  • [38] Efficacy and safety of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer
    Qian, Yeqiang
    Wu, Hefang
    Gao, Lu
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2024, 45 (03) : 68 - 74
  • [39] First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)
    Kok, M.
    Voorthuis, R. A. B.
    De Boo, L.
    van Rossum, A. G. J.
    Mandjes, I.
    Balduzzi, S.
    Chelushkin, M.
    Rosenberg, E. H.
    Horlings, H. M.
    Loo, C. E.
    Heijns, J. B.
    Agterhof, M.
    De Valk, B.
    Riel, A-M. V.
    Van der Velden, A.
    Dercksen, M.
    Imholz, A.
    van Leeuwen-Stok, A. E.
    Oosterkamp, H. M.
    Linn, S.
    ANNALS OF ONCOLOGY, 2024, 35 : 1213 - 1213
  • [40] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
    Obeid, E.
    Miller, K. D.
    Sparano, J. A.
    Blackwell, K.
    Goldstein, L. J.
    CANCER RESEARCH, 2017, 77
12345